FY2025 · ended Dec 31, 2025 · Revenue $296,000, -41.9% YoY · Filed Mar 3, 2026
ABVC BioPharma, Inc. (ABVC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $296,000 and a net loss of $7.9 million. As of Jun 30, 2026 it held $2.6 million in cash and investments and $1.8 million in total debt.
Revenue
$296,000
-41.9% vs prior year
Net income
$-7.91M
-61.3% vs prior year
Operating cash flow (TTM)
$-2.69M
-29.6% vs year-ago TTM
Free cash flow
$-4.21M
+44.0% vs prior year
EPS
$-0.39
+7.1% vs prior year
Dividend per share
None
Shares outstanding
25.44M
+61.2% vs prior year
Net cash
$761,009
as of Jun 30, 2026
Operating margin
-2416.0%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABVC (Nasdaq), ECOC (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Fremont, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1173313
- Former names
- American BriVision (Holding) Corp (until Apr 8, 2021); METU BRANDS, INC. (until Jan 8, 2016); Ecology Coatings, Inc. (until Sep 2, 2015); ECOLOGY COATINGS, INC. (until Sep 2, 2015); OCIS CORP (until Jun 13, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $296,000 | $509,589 | $152,430 | $969,783 | $355,797 |
| Operating income | -$7.2M | -$4.7M | -$6.8M | -$15.1M | -$11.7M |
| Net income | -$7.9M | -$4.9M | -$7.8M | -$16.4M | -$12.8M |
| Diluted EPS | -$0.39 | -$0.42 | -$1.80 | -$5.19 | -$0.51 |
| Operating cash flow | -$3.0M | -$1.8M | -$4.2M | -$7.4M | -$7.6M |
| Free cash flow | — | — | -$4.2M | -$7.5M | -$7.6M |
| Total assets | $21.1M | $7.5M | $7.8M | $9.6M | $13.7M |
| Total liabilities | $7.8M | $6.8M | $6.5M | $6.3M | $4.8M |
| Stockholders' equity | $11.1M | $1.2M | $1.6M | $3.1M | $8.8M |
| Cash and investments | $2.6M | $2.6M | $2.7M | $1.0M | $6.9M |
| Total debt | $2.7M | $1.5M | $1.7M | $2.1M | $2.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Unregistered share sale, Shareholder vote results, Regulation FD disclosure
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
|
Aug 27, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Other events
|
Aug 12, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Other events
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Auditor change
|
Jul 2, 2026 | Jul 2, 2026 |
All 795 ABVC BioPharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.